News | Stents Drug Eluting | February 19, 2018

Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent

Recently approved by FDA, the EluNIR drug-eluting stent opens clogged arteries to restore blood flow in tortuous anatomy of patients with coronary artery disease

 

Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent

February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently became the first in Michigan to offer patients with coronary artery disease a new treatment option for vessels that are difficult to stent because of the size and intricacy.

Tamam Mohamad, M.D., chief of cardiology at DMC Detroit Receiving Hospital, treated 60-year-old Haila Alamri, the mother of nine children and an armful of grandchildren, who was experiencing angina, with pressure in her chest, after walking short distances. The symptoms caused her a lot of fear and anxiety and greatly affected her quality of life.

Mohamad completed the procedure guiding the newly U.S. Food and Drug Administration (FDA)-approved EluNIR stent through a complex, circuitous course of blood vessels to reach and open a main artery that was 90 percent blocked. The three-hour procedure brought the blockage to 0 percent, and Friday, Haila Alamri went home the next day.

The EluNIR drug-eluting stent has the narrowest strut width of any FDA-approved stent currently available in the U.S. This low-profile stent, with radiopaque spring tip, makes it easier to maneuver in heavily calcified or intricately curved blood vessels.

“At the DMC, we strive to provide our patients with the newest treatment options to best serve their cardiac needs,” said Mohamad. “It’s the same kind of care I would provide for my own family.”

Mahir Elder, M.D., director of endovascular medicine at the DMC Heart Hospital, added, “The DMC Cardiovascular team's goal is to stay on the forefront of technology. As leading physicians in the field, we strive to bring the latest and greatest technology and innovation to the metro Detroit community.”

Cardiovascular disease is the No. 1 killer in the United States. According to the American Heart Association, each day about 2,200 Americans die from cardiovascular disease, about one person every 40 seconds.

During Heart Month, the DMC Cardiovascular team recommends patients seek medical attention immediately if they are experiencing any of the following common symptoms of a heart attack:

  • Severe pressure, fullness, squeezing, pain or discomfort in the center of the chest that lasts for more than a few minutes;
  • Pain or discomfort that spreads to the shoulders, neck, arms or jaw;
  • Chest pain that gets worse;
  • Chest pain that does not get better with rest or by taking nitroglycerin;
  • Chest pain that happens along with any of these symptoms:
    • Sweating, cool, clammy skin, or paleness
    • Shortness of breath
    • Nausea or vomiting
    • Dizziness or fainting
    • Unexplained weakness or fatigue
    • Rapid or irregular pulse

Although chest pain is the key warning sign of a heart attack, it may be confused with other conditions. These include indigestion, pleurisy, pneumonia, tenderness of the cartilage that attaches the front of the ribs to the breastbone, and heartburn.

For more information: www.dmc.org

Related Content

Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System

Medinol Announces Positive 12-Month Trial Results for EluNIR Drug-Eluting Stent

Detroit Cardiogenic Shock Initiative Goes National at TCT 2017

DMC Heart Hospital Completes Complex High-Risk Indicated Interventional Procedure Course

Related Content

Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...
News | Cath Lab | December 18, 2019
December 18, 2019 — Cook Medical initiated a recall of its CrossCath Support Catheters in November, which the U.S.